HEMO BIOENGINEERING PTE. LTD.

Headquartered in Singapore, HEMO Bioengineering is an innovative medical device company focused on developing advanced solutions for neuro-interventional treatment. Our mission is to improve patients’ health and quality of life through innovative, clinically relevant medical technologies.

HEMO has built a comprehensive portfolio of neuro-interventional medical devices covering ischemic stroke, hemorrhagic stroke and neurovascular access. Among our key innovations is AsprAX™, a super large-bore aspiration catheter designed to support mechanical thrombectomy procedures and representing one of the largest-bore aspiration catheter platforms commercialized outside the United States.

With corporate, R&D and production capabilities across Singapore, China, the United States and Malaysia, HEMO combines global product development expertise with an expanding international commercial presence across Europe, Asia and the Middle East. Our R&D activities are further supported by a network of key opinion leaders, clinicians and industry experts who provide valuable insights into clinical needs and product development.

HEMO's leadership team comprises experienced professionals from the global medical device industry, including veterans of established multinational and Fortune 500 companies. The Group was founded by Chairman Professor Jack Wang, an experienced medtech entrepreneur who previously served as CEO of SGX Mainboard-listed Biosensors International Group and JW Medical Systems.

HEMO operates under an EN ISO 13485-certified quality management system and maintains medical device production capabilities supported by certified controlled-environment facilities. Our neuro-interventional portfolio includes products with CE MDR certification, supporting their commercialization in the European market and other international markets.

In addition to developing and commercializing our proprietary neuro-interventional technologies, HEMO is open to manufacturing and strategic product partnerships, including manufacturing support for established medical devices and collaboration with international medical device companies seeking experienced development and production capabilities.

Through continuous innovation, international collaboration and a strong focus on unmet clinical needs, HEMO aims to become a trusted global partner in the advancement of neurovascular intervention.